Coherus BioSciences
(NASDAQ:CHRS)
$2.12
0[0.00%]
At close: May 20
$2.12
0[0.00%]
PreMarket: 8:26AM EDT
Consensus Rating1
Buy
Highest Price Target1
$21.00
Lowest Price Target1
$7.00
Consensus Price Target1
$10.00

Coherus BioSciences Stock (NASDAQ:CHRS), Analyst Ratings, Price Targets, Predictions

Coherus BioSciences Inc has a consensus price target of $10, established from looking at the 39 latest analyst ratings. The last 3 analyst ratings were released from Truist Securities, HC Wainwright & Co., and HC Wainwright & Co. on May 13, 2024, May 10, 2024, and March 20, 2024. With an average price target of $10 between Truist Securities, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 371.70% upside for Coherus BioSciences Inc from these 3 analyst ratings.

Analyst Trend
1
Nov 23
2
Dec 23
2
Jan
2
Mar
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Truist Securities
HC Wainwright & Co.
Baird
Maxim Group
Barclays

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Coherus BioSciences

Buy NowGet Alert
05/13/2024Buy Now230.19%Truist Securities
Robyn Karnauskas
$8 → $7MaintainsBuyGet Alert
05/10/2024Buy Now466.04%HC Wainwright & Co.
Douglas Tsao
$11 → $12MaintainsBuyGet Alert
03/20/2024Buy Now418.87%HC Wainwright & Co.
Douglas Tsao
$13 → $11MaintainsBuyGet Alert
03/14/2024Buy Now513.21%HC Wainwright & Co.
Douglas Tsao
→ $13ReiteratesBuy → BuyGet Alert
01/23/2024Buy Now324.53%Baird
Colleen Kusy
$11 → $9MaintainsOutperformGet Alert
01/23/2024Buy Now277.36%Truist Securities
Robyn Karnauskas
$12 → $8MaintainsBuyGet Alert
12/27/2023Buy Now513.21%HC Wainwright & Co.
Douglas Tsao
→ $13ReiteratesBuy → BuyGet Alert
12/07/2023Buy Now513.21%HC Wainwright & Co.
Douglas Tsao
→ $13ReiteratesBuy → BuyGet Alert
11/28/2023Buy Now466.04%Truist Securities
Robyn Karnauskas
→ $12ReiteratesBuy → BuyGet Alert
11/17/2023Buy Now418.87%Baird
Colleen Kusy
→ $11Initiates → OutperformGet Alert
11/08/2023Buy NowMaxim Group
Jason McCarthy
DowngradeBuy → HoldGet Alert
11/07/2023Buy Now513.21%HC Wainwright & Co.
Douglas Tsao
$20 → $13MaintainsBuyGet Alert
10/23/2023Buy Now230.19%Barclays
Balaji Prasad
$8 → $7MaintainsOverweightGet Alert
09/26/2023Buy Now843.4%Truist Securities
Robyn Karnauskas
→ $20ReiteratesBuy → BuyGet Alert
09/26/2023Buy Now843.4%HC Wainwright & Co.
Douglas Tsao
→ $20ReiteratesBuy → BuyGet Alert
08/03/2023Buy Now843.4%HC Wainwright & Co.
Douglas Tsao
$24 → $20MaintainsBuyGet Alert
07/24/2023Buy Now466.04%Citigroup
Robyn Karnauskas
→ $12Initiates → BuyGet Alert
07/14/2023Buy Now843.4%Truist Securities
Robyn Karnauskas
$22 → $20MaintainsBuyGet Alert
06/28/2023Buy Now937.74%Truist Securities
Robyn Karnauskas
→ $22ReiteratesBuy → BuyGet Alert
06/20/2023Buy Now937.74%Truist Securities
Robyn Karnauskas
$24 → $22MaintainsBuyGet Alert
06/20/2023Buy Now1032.08%HC Wainwright & Co.
Douglas Tsao
→ $24ReiteratesBuy → BuyGet Alert
06/15/2023Buy Now1032.08%Truist Securities
Robyn Karnauskas
→ $24ReiteratesBuy → BuyGet Alert
06/06/2023Buy Now1032.08%HC Wainwright & Co.
Douglas Tsao
→ $24Reiterates → BuyGet Alert
06/01/2023Buy Now1032.08%HC Wainwright & Co.
Douglas Tsao
→ $24ReiteratesBuy → BuyGet Alert
05/23/2023Buy Now277.36%Barclays
Balaji Prasad
$13 → $8MaintainsOverweightGet Alert
05/09/2023Buy Now1032.08%HC Wainwright & Co.
Douglas Tsao
$26 → $24MaintainsBuyGet Alert
05/01/2023Buy Now1032.08%Truist Securities
Robyn Karnauskas
→ $24Initiates → BuyGet Alert
03/28/2023Buy Now418.87%UBS
Ashwani Verma
→ $11UpgradeNeutral → BuyGet Alert
03/08/2023Buy Now513.21%Barclays
Balaji Prasad
$15 → $13MaintainsOverweightGet Alert
03/07/2023Buy Now1126.42%HC Wainwright & Co.
Douglas Tsao
$30 → $26MaintainsBuyGet Alert

FAQ

Q

What is the target price for Coherus BioSciences (CHRS)?

A

The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Truist Securities on May 13, 2024. The analyst firm set a price target for $7.00 expecting CHRS to rise to within 12 months (a possible 230.19% upside). 25 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Coherus BioSciences (CHRS)?

A

The latest analyst rating for Coherus BioSciences (NASDAQ: CHRS) was provided by Truist Securities, and Coherus BioSciences maintained their buy rating.

Q

When was the last upgrade for Coherus BioSciences (CHRS)?

A

The last upgrade for Coherus BioSciences Inc happened on March 28, 2023 when UBS raised their price target to $11. UBS previously had a neutral for Coherus BioSciences Inc.

Q

When was the last downgrade for Coherus BioSciences (CHRS)?

A

The last downgrade for Coherus BioSciences Inc happened on November 8, 2023 when Maxim Group changed their price target from N/A to N/A for Coherus BioSciences Inc.

Q

When is the next analyst rating going to be posted or updated for Coherus BioSciences (CHRS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Coherus BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Coherus BioSciences was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.

Q

Is the Analyst Rating Coherus BioSciences (CHRS) correct?

A

While ratings are subjective and will change, the latest Coherus BioSciences (CHRS) rating was a maintained with a price target of $8.00 to $7.00. The current price Coherus BioSciences (CHRS) is trading at is $2.12, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch